Jacobio Pharmaceuticals Co.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Jacobio Pharmaceuticals Co. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 3 currently recruiting 4 completed early-phase tilt upper quartile by trial count

Jacobio Pharmaceuticals Co.: 7 sponsored US clinical trials, 3 recruiting.

Jacobio Pharmaceuticals Co. sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 2 trials.

Upper-quartile sponsor footprint

Jacobio Pharmaceuticals Co. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

NCT06973564
RECRUITING Phase 1

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

NCT06386146
RECRUITING Phase 1

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

NCT05490472
COMPLETED Phase 1

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NCT05002270
COMPLETED Phase 1

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

NCT04587479
COMPLETED Phase 1

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

NCT04045496
COMPLETED Phase 1

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

NCT03518554

Phase Distribution

PhaseTrial count
Phase 1 7

Therapeutic Areas

Solid Tumors 2
Other Metastatic Solid Tumors 1
ARID1A Gene Mutation 1
Small Cell Lung Cancer (SCLC) 1
ER+ Breast Cancer 1
Triple Negative Breast Cancer (TNBC) 1
CRC 1
NSCLC 1
Esophageal Cancer 1
Advanced Solid Tumors 1

What is open in the Jacobio Pharmaceuticals Co. pipeline

3 recruiting of 7 indexed (43% open); 4 completed (57%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Solid Tumors (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Jacobio Pharmaceuticals Co.: open-pipeline peers nationwide

Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.

Jacobio Pharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 6.97.07.077.07.07.1 0%10%20%30%40%50% Total trials Recruiting share Jacobio Pharmaceuticals Co.3M4Life Research89bioAbbott Diagnostics DivisionAlphatec SpineClarity PharmaceuticalsColorado Center for Reproductive MedicineDavid Moss
Jacobio Pharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Jacobio Pharmaceuticals Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 43% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Jacobio Pharmaceuticals Co. page

7 registered trials is a research-attention snapshot, not an endorsement of Jacobio Pharmaceuticals Co. or any single study.

  • 3 of Jacobio Pharmaceuticals Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Solid Tumors is the condition Jacobio Pharmaceuticals Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jacobio Pharmaceuticals Co. pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.